High p-Smad2 expression in stromal fibroblasts predicts poor survival in patients with clinical stage I to IIIA non-small cell lung cancer.
High p-Smad2 expression in stromal fibroblasts predicts poor survival in patients with clinical stage I to IIIA non-small cell lung cancer.
复制标题
DOI：
10.1186/1477-7819-12-328
复制
发表时间：
2014-11-05
影响因子：
3.2
通讯作者：
Lu X
中科院分区：
文献类型：
--
作者：
Chen Y;Xing P;Chen Y;Zou L;Zhang Y;Li F;Lu X
越来越多的证据表明TGFβ/Smad信号通路在肿瘤的发生、发展和转移中起重要作用。因此，我们研究p-Smad 2在非小细胞肺癌手术切除标本中的表达，并评估p-Smad 2在间质成纤维细胞和癌细胞中的表达对临床I期至IIIA期非小细胞肺癌患者的预后意义。应用免疫组化方法检测78例临床I期至IIIA期非小细胞肺癌手术切除标本中p-Smad 2的表达。采用卡方检验分析p-Smad 2表达与临床病理特征的相关性。通过Kaplan-Meier法确定基质成纤维细胞和癌细胞中p-Smad 2表达对总生存期的预后意义。p-Smad 2在间质成纤维细胞和癌细胞中的高表达率分别为38.5%（30/78）和92.3%（72/78）。间质成纤维细胞中p-Smad 2的表达水平与癌细胞中p-Smad 2的表达水平呈正相关（χ2 = 4.176，P =0.045）。间质成纤维细胞和癌细胞中pSmad 2表达与临床病理特征无明显相关性，间质成纤维细胞中pSmad 2低表达和高表达的3年总生存率分别为53.7%和37.7%（χ2 = 3.86，P = 0.049）。p-Smad 2在癌细胞中的低表达和高表达与总生存率无显著相关性（χ2 = 0.34，P =0.562）。结果表明，间质成纤维细胞中p-Smad 2的高表达预示着临床I期至IIIA期非小细胞肺癌患者的生存率低。
Increasing evidence indicates that the TGFβ/Smad signaling pathway plays a prominent role in tumor initiation, progression, and metastasis. Therefore, we investigate the expression of p-Smad2 in surgical resection specimens from non-small cell lung cancer, and evaluate the prognostic significance of p-Smad2 expression in stromal fibroblasts and cancer cells for patients with clinical stage I to IIIA non-small cell lung cancer. The immunohistochemical expression of p-Smad2 was evaluated in 78 formalin-fixed paraffin-embedded surgical resection specimens from clinical stage I to IIIA non-small cell lung cancer. Correlations between p-Smad2 expression and clinicopathologic characteristics were determined by Chi-square test. The prognostic significance of p-Smad2 expression in stromal fibroblasts and cancer cells with regard to overall survival was determined by Kaplan-Meier. There were 38.5% (30/78) and 92.3% (72/78) patients with high p-Smad2 expression in stromal fibroblasts and cancer cells, respectively. There was a positive correlation between the p-Smad2 expression level in stromal fibroblasts and the p-Smad2 expression level in cancer cells (χ2 = 4.176, P =0.045). No significant correlation of p-Smad2 expression in stromal fibroblasts or cancer cells with any of clinicopathologic characteristics was found. The 3-year overall survival rates with low and high p-Smad2 expression in stromal fibroblasts were 53.7% and 37.7%, respectively (χ2 = 3.86, P = 0.049). No significant association was found between low and high p-Smad2 expression in cancer cells with respect to overall survival, respectively (χ2 = 0.34, P =0.562). The results suggested that high p-Smad2 expression in stromal fibroblasts predicted poor survival in patients with clinical stage I to IIIA non-small cell lung cancer.
登录
查看更多内容
影响因子：
11.2
作者：
Mantoni TS;Lunardi S;Al-Assar O;Masamune A;Brunner TB
通讯作者：
Brunner TB
影响因子：
3.3
作者：
Park, Jeong Hwan;Lee, Cheol;Moon, Kyung Chul
通讯作者：
Moon, Kyung Chul
影响因子：
50.3
作者：
Bruna, Alejandra;Darken, Rachel S.;Seoane, Joan
通讯作者：
Seoane, Joan
影响因子：
4.6
作者：
Kim, Chi Hong;Park, Sonya Youngju;Yoo, Jinyoung
通讯作者：
Yoo, Jinyoung
影响因子：
2.9
作者：
Xu Z;Wang S;Wu M;Zeng W;Wang X;Dong Z
通讯作者：
Dong Z